Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/364796


U.S. Pharmacogenomics Markets


Description:

Pharmacogenomics Pave the Way for Genetically Tailored Drugs

The identification of the human genome's chain sequence is revolutionizing the biotechnology and pharmaceuticals industries. Pharmacogenomics analyzes how an individual's genetic inheritance affects the body's variable response to drugs. By understanding each patient at such a profound level, pharmaceutical
manufacturers will eventually be able to produce personalized drugs that meet the unique needs of an individual's genetic makeup. Tailor-made medicines
could all but eliminate harmful drug interactions while enhancing drug efficacy, safety, and improving patients' treatments.

The field of pharmacogenomics targets specific genes for therapeutics, as well as screens genes for potential drug interactions, aiding pharmaceuticals in the
development of highly sophisticated medications. This study assesses the future of markets for genetic services (such as genetic screening), gene-based
diagnostics, and drug development for rare genetic diseases. With this in-depth research at your fingertips, your company will be poised to capitalize
on a burgeoning field.

Key Alliances and Pro-active Networking Efforts Essential for Success

Investors and established companies should begin scouting start-up companies and academic laboratories for innovative technologies, says the study's author. Forging alliances with universities' technology transfer offices, teaching hospitals, and large research institutions are crucial for market expansion.

At the same time, it is essential for participants to attend industry organization conferences to network with financial supporters of this field. Companies need to be visible and promote themselves as advocates of new
ventures, says the author. This study highlights industry challenges and offers strategic recommendations to help maximize your revenue-generating potential.

Overseas Markets Hold Promise for Orphan Drugs

Stringent healthcare regulations in foreign countries can make it difficult for pharmaceutical companies to introduce new products overseas. As the author states, The 'orphan' designation, which applies to a very select population of patients, may be an exception to the rule.

However, orphan drugs, which treat rare genetic diseases affecting tiny populations, could meet lower market barriers. It is conceivable that a wider
interpretation of compassionate use could apply to 'orphan' drugs, says the author. This analysis surveys laws that will impact the development of the field, helping you anticipate and overcome obstacles that might lie ahead.


Contents: 1. Executive Summary
A. Market Overview

1. Pharmacogenomics and Polymorphisms

2. The Advantages of Pharmacogenomics

3. Market for Pharmacogenomics
B. Analysis by Major Segment

1. Overview

2. Service Market of Pharmacogenomics

3. Diagnostics

4. Orphan Drugs

5. Overall Trends

6. Competitive Analysis

7. Technologies

2. Market Engineering Analysis of the Pharmacogenomics Market
A. Research Scope

1. Objectives and Validation

2. Structure and Segmentation

3. Forecast Period -Milestones
B. Methodology and Definitions

1. Research Methodology

2. List of Definitions

3. List of Acronyms
C. Total Market Analysis

1. Market Overview

2. Market Challenges

3. Market Drivers

4. Market Restraints

5. Market Forecast
D. Conclusion

1. Recommendations

2. Concluding Remarks
E. Market Engineering Awards

1. Market Engineering Awards

2. Marketing Strategy Award

3. Product Differentiation Innovation Award

4. Product Launch Strategy Award

5. Technology Innovation Award

6. Technology Leadership Award

3. Market Analysis of Pharmacogenomics Services
A. Service Market

1. Overview and Definition

2. The Present Market for Services and Forecast

3. Maintaining Intellectual Property

4. Integrating Pharmacogenomics into the Development of Drugs

5. Adopting Pharmacogenomics into the Research and Development Process
B. Microarrays Market

1. Overview and Definition

2. Competitive Assessment

3. Alternative to Microarrays

4. Evaluation of the Microarray Market
C. Bioinformatics Market

1. Overview and DefinitioN

2. Role of Databanks in Pharmacogenomics

3. Bioinformatics Software

4. Market Analysis of Gene-Based Diagnostics
A. Present Status of Diagnostics in Pharmacogenomics

1. Overview

2. The Market for the TPMT Test

3. A Vast and Underestimated Market
B. Future Status for Diagnostics in Pharmacogenomics

1. The Promise from Pharmacogenomics

2. Diagnostics Model 1

3. Diagnostics Model 2

4. Forecasting the Winning Model

5. Market Analysis of Orphan Drugs
A. Background

1. Overview and Definition

2. Precedent for Gene-Based Drugs

3. Legislation Around Orphan Drugs

4. Market for Orphan Drugs

5. Implications of Strategies Devised to Improve Orphan Drugs' Profitability
B. The Present Market for Orphan Drugs

1. Revenues for Orphan Drugs

2. Marketing Models for Orphan Drugs

3. Airline Consortium Model

4. Organic Growth Model

5. Marginal Revenues Model
C. The Future for Orphan Drugs

1. Overview and Definitions

2. Pharmacoeconomics Applied to Orphan Drugs

3. International Dimension for Orphan Drug Market

4. Emerging Trends for Orphan Drugs

6. Database of Key Industry Participants
This chapter presents a comprehensive database of the key industry participants with names, addresses, and phone numbers. It is provided as a support tool to aid clients in acquisition searches, continuing research, strategic alliances, and market monitoring.

List Of Figures

Chapter 1

- Pharmacogenomics Market: Size of Market (U.S.), 2000
- Pharmacogenomics Market: Segmentation of Industry and Estimate of Size of Each Segment (U.S.), 2001-2010

Chapter 2

- Pharmacogenomics Market: Anticipated Milestones for the Market (U.S.), 2001-2010
- Pharmacogenomics Market: Selected Websites of Interest (U.S.), 2001
- Total Pharmacogenomics Market: Impact of Top Fourteen Industry Challenges (U.S.), 2000-2006
- Total Pharmacogenomics Market: Market Drivers Ranked in Order of Impact (U.S.), 2000-2006
- Total Pharmacogenomics Market: Market Restraints Ranked in Order of Impact (U.S.), 2000-2006
- Pharmacogenomics Market: Size of Market and Revenue Forecasts (U.S.), 2000-2005
- Total Pharmacogenomics Market: Strategies Addressing Top Fourteen Market Challenges (U.S.), 2001

Chapter 3

- Pharmacogenomics Market: Revenue Forecasts(U.S.), 2000-2005
- Pharmacogenomics Market: Seven-Step Market Engineering Forecast Methodology (U.S.), 2001
- Pharmacogenomics Market: Representative Microarray Technologies on the Market and Companies Involved (U.S.), 2001
- Pharmacogenomics Market: National Institutes Involved in Generating and Maintaining NIH-based Databank for Pharmacogenomics (U.S.), 2001
- Pharmacogenomics Market: List of Companies Involved in the SNP Consortium, 2001

Chapter 4

- Pharmacogenomics Diagnostics Market: Revenue Forecasts for Model 1 (U.S.), 2000-2005
- Pharmacogenomics Diagnostics Market: Revenue Forecasts for Model 2 (U.S.), 2000-2005
- Pharmacogenomics Diagnostics Market: Size and Annual Growth for Gene-based Diagnostics - Model 1 vs. Model 2 Forecasts (U.S.), 2000-2005

Chapter 5

- Orphan Drugs Market: Population of Countries Dealing with Orphan Legislation (World), 2001
- Orphan Drugs Market: Fluctuation in Number of Drugs Receiving Orphan Designation (U.S.), 1983-2000
- Orphan Drugs Market: Designation for Orphan Drugs (World), 1993-2000
- Resurrecting a Drug: The Case of Thalidomide (U.S.), 1988-1999
- Resurrection of Drugs: The Thalidomide Model (U.S.), 1998-2000
- Revenues from Orphan Drugs: Airline Consortium Model -Data from a Company Specialized in the Drugs (U.S.), 1999-2000
- Revenues from Orphan Drugs: Self-Made Man Model -Data from a Company Specialized in the Drugs (EU), 2000-2005
- Revenues from Orphan Drugs: Self-Made Man Model -Data from a Company Specialized in the Drugs Based on Growth of Personnel (EU), 1990-2004
- Pharmacogenomics Orphan Drugs Market: Revenue Forecasts (U.S.), 2000-2005

List of Charts

Chapter 2

- Pharmacogenomics: Schematic Relationships Among Market Forces (U.S.), 2001

Chapter 3

- Pharmacogenomics: The Service Market (U.S.), 2001

Chapter 4

- Pharmacogenomics Diagnostics Market: Size and Annual Growth for Gene-based Diagnostics -Model 1 vs. Model 2 Forecasts (U.S.), 2000-2005

Chapter 5

- Resurrection of Drugs: The Thalidomide Model (U.S.), 1998-2000
- Revenues from Orphan Drugs: Airline Consortium Model -Data from a Company Specialized in the Drugs (U.S.), 1999-2000




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/364796

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 28/11/2009 19:12:05
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
U.S. Pharmacogenomics Markets
Web Address:
http://www.researchandmarkets.com/reports/364796
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License €2,989.00
Electronic (PDF) - Enterprisewide €3,996.00
Electronic and Hard Copy (PDF) - Enterprisewide €4,332.00 + EUR€ 50.00 Shipping/Handling *
Electronic and Hard Copy (PDF) - Site License €3,324.00 + EUR€ 50.00 Shipping/Handling *
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 28/11/2009 19:12:05

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)